Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).

Journal:

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Volume: 76, Issue: 3

Published:

February 8, 2023

PMID:

36041016

Authors:

April C Pettit AC, Patrick P J Phillips PPJ, Ekaterina Kurbatova E, Andrew Vernon A, Payam Nahid P, Rodney Dawson R, Kelly E Dooley KE, Ian Sanne I, Ziyaad Waja Z, Lerato Mohapi L, Anthony T Podany AT, Wadzanai Samaneka W, Rada M Savic RM, John L Johnson JL, Grace Muzanyi G, Umesh G Lalloo UG, Kia Bryant K, Erin Sizemore E, Nigel Scott N, Susan E Dorman SE, Richard E Chaisson RE, Susan Swindells S,

Access Paper

DOI: 10.1093/cid/ciac707

PMID: 36041016

Abstract:

Tuberculosis (TB) Trials Consortium Study 31/AIDS Clinical Trials Group A5349, an international randomized open-label phase 3 noninferiority trial showed that a 4-month daily regimen substituting rifapentine for rifampin and moxifloxacin for ethambutol had noninferior efficacy and was safe for the treatment of drug-susceptible pulmonary TB (DS-PTB) compared with the standard 6-month regimen. We explored results among the prespecified subgroup of people with human immunodeficiency virus (HIV) (PWH).

Courtesy of the U.S. National Library of Medicine